Fulgent Genetics

Fulgent Genetics Liabilities

The The Liabilities of Fulgent Genetics (FLGT) as of Nov 2, 2026 is 106.81 M USD. In the previous year, The Liabilities was 90.81 M USD — a change of 17.63% (higher).

Liabilities

106.81 MUSD

YoY

17.63%

Last updated:

In 2025, Fulgent Genetics's total liabilities amounted to 106.81 M USD, a 17.63% difference from the 90.81 M USD total liabilities in the previous year.

The Fulgent Genetics Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
2.75 M USD
Jan 1, 2019
5.98 M USD
Jan 1, 2020
131.07 M USD
Jan 1, 2021
112.84 M USD
Jan 1, 2022
116.18 M USD
Jan 1, 2023
102.04 M USD
Jan 1, 2024
90.81 M USD
Jan 1, 2025
106.81 M USD
The Fulgent Genetics Liabilities history
YEARLiabilitiesYoY
106.81 MUSD+17.63%
90.81 MUSD-11.01%
102.04 MUSD-12.17%
116.18 MUSD+2.96%
112.84 MUSD-13.91%
131.07 MUSD+2,092.24%
5.98 MUSD+117.81%
2.75 MUSD-6.15%
2.93 MUSD-17.86%
3.56 MUSD+419.10%
686,000.00USD+57.34%
436,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Fulgent Genetics Stock analysis

What does Fulgent Genetics do? Fulgent Genetics Inc. is a US company founded in 2011 by Jianxing (Justin) Liu and Ming Hsieh. The company has undergone remarkable development and is now active in the field of genomics and genetics. Fulgent Genetics' business model is based on the development and distribution of solutions for the diagnosis of genetic diseases. The company offers a variety of products and services that enable doctors, clinics, and laboratories to make effective diagnoses based on genetics. One of Fulgent Genetics' main divisions is the Clinical Diagnostics department, which offers a wide range of diagnostic products that allow for both molecular diagnoses and the creation of clinical profiles for patients. This enables doctors and clinics to quickly and accurately detect and treat specific diseases. Another important division of Fulgent Genetics is the Research department, which focuses on the discovery and development of new technologies and testing procedures. These technologies and procedures are of great interest to the scientific community and are used in research or clinical studies. Fulgent Genetics also offers a Pharmacogenomics department, which is a growing segment in the personalized medicine market. The goal here is to tailor medications to the patient's genetic makeup. Fulgent Genetics' technology allows for the analysis of a patient's current genetic makeup and recommends medications based on that. Another important area of Fulgent Genetics is the direct-to-consumer sales of tests. This is particularly significant in the field of ancestry and genealogy research. Fulgent Genetics offers a variety of tests in this area and has already achieved great success. Overall, Fulgent Genetics offers a wide range of products and services mainly focused on the diagnosis of genetic diseases. However, the company also goes beyond that and provides solutions for a wide range of customers and applications. Fulgent Genetics is based in the US and has experienced rapid growth since its founding. The company's success is also reflected in the many awards it has received. It has been recognized multiple times and has established a reputation as one of the leading biotechnology companies in the world. Fulgent Genetics is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Fulgent Genetics's Liabilities

Fulgent Genetics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Fulgent Genetics's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Fulgent Genetics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Fulgent Genetics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Fulgent Genetics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Fulgent Genetics stock

The Liabilities of Fulgent Genetics is 106.81 M USD in 2025.

The Liabilities of Fulgent Genetics changed from 90.81 M USD to 106.81 M USD, representing a 17.63% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Fulgent Genetics since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Fulgent Genetics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Fulgent Genetics

All Key Metrics — Fulgent Genetics